Emily R. Schulman


Schulman, Emily R.

Emily Schulman has extensive trial and appellate experience in white-collar matters. She has briefed and argued dozens of cases before the United States Courts of Appeals, and has tried more than 20 jury trials in the United States District Courts. Her practice focuses on internal and governmental investigations and white collar defense. Prior to joining private practice, Ms. Schulman served as an Assistant United States Attorney in the US Attorney's Office in Massachusetts.

For more than a decade, Ms. Schulman served as an Assistant United States Attorney in the US Attorney's Office in Massachusetts, investigating and prosecuting economic and white-collar fraud, money laundering and tax violations, and political and public corruption cases. She has extensive experience representing companies, boards of directors and their committees, and individuals in internal investigations, criminal litigation, government enforcement actions, and federal and state grand jury investigations involving allegations of health care fraud, false claims, economic fraud and securities violations.

Honors & Awards

  • Selected by her peers for inclusion in the 2014 edition of The Best Lawyers in America for her work in criminal defense: white-collar.
  • Recognized as a leading attorney in the 2013 and 2014 editions of The International Who’s Who of Business Crime Defence Lawyers.
  • Named a "Life Sciences Star" for outstanding government enforcement/investigations work in the 2012 and 2013 editions of LMG Life Sciences.
  • Selected as a Fellow of the Litigation Counsel of America, a peer-nominated, invitation only Trial Lawyer Honorary Society.
  • Recognized as Life Science Star by LMG Life Sciences 2012 for White Collar Defense and Government Investigations.

Publications & News


February 24, 2014

Fourth Circuit Holds cGMP Violations Do Not Create False Claims Under Medicare and Medicaid

In the first appellate decision of its kind, the U.S. Court of Appeals for the Fourth Circuit held on February 21, that because compliance with the Food and Drug Administration’s Current Good Manufacturing Practices (cGMP)  regulations is not a precondition for reimbursement under Medicare and Medicaid, violations of the cGMP regulations by themselves cannot form the basis for False Claims Act claims under those programs.

August 15, 2013

Best Lawyers in America® 2014 Recognizes Nearly 100 WilmerHale Partners, Naming Eight “Lawyer of the Year”

Nearly 100 WilmerHale lawyers have been selected for inclusion in the 20th edition of The Best Lawyers in America®—a respected peer-review publication in the legal industry. The 2014 list also highlights eight WilmerHale partners who have been named "Lawyer of the Year" by Best Lawyers.

June 17, 2013

WilmerHale Earns Top Rankings in LMG Life Sciences Guide

The 2013 edition of LMG Life Sciences has been released, and it includes the recognition of nine WilmerHale practice areas and 17 attorneys.

March 11, 2010

FDA Plans to Increase Strict Liability Criminal Prosecutions of Corporate Executives

November 13, 2007

WilmerHale Names New Partners and Counsel for 2008

Recent Highlights

  • Represented pharmaceutical company in multiple, multi-year parallel civil and criminal investigations focusing on off-label marketing, Anti-kickback and false claims allegations;
  • Represented pharmaceutical company in multi-year parallel civil and criminal investigation focusing on cGMP compliance, manufacturing practices, and the shipment of allegedly adulterated products;
  • Conducted internal investigation for pharmaceutical company focusing on Anti-kickback allegations;
  • Represented pharmaceutical company in congressional inquiry into payments to healthcare professionals;
  • Represented medical products manufacturer in securities fraud class action, securing denial of class certification and dismissal of case;
  • Represented hedge fund Founder and Lead Portfolio manager in SEC insider-trading investigation, securing dismissal of case;
  • Represented hedge fund Founder and Lead Portfolio manager in parallel federal criminal and SEC insider trading investigation;
  • Represented financial software company in securities fraud class action, securing denial of class certification and dismissal of case;
  • Conducted internal investigation for Board of Directors of financial institution focusing on internal audit and economic modeling functions;
  • Represented Special Committee of communications technology company in SEC fraud investigation and administrative delisting proceedings, securing dismissal of case and administrative proceedings;
  • Represent S&P 500 technology company in parallel federal civil and criminal fraud investigation;
  • Represented former Chief Financial Officer and Chief Operating Officer of semi-conductor manufacturing company in SEC fraud investigation, securing dismissal of case;
  • Represented Director of Marketing in federal Anti-kickback and false claims investigation;
  • Represented CFO and Chief Compliance Officer of investment management company in SEC investigation and collateral administration proceedings concerning alleged market manipulation, securities fraud and disclosure violations. 

Professional Activities

Ms. Schulman has been a Visiting Lecturer at Harvard Law School since 2010. In 2013, she was a Visiting Professor at Srednerusskiy University in Russia, teaching US Criminal Law and Criminal Procedure. She has also been a Visiting Assistant Professor at Villanova University School of Law, teaching courses on criminal law, criminal procedure and white-collar crime. Ms. Schulman has conducted trainings nationally and internationally on criminal investigatory and enforcement matters and developments in healthcare and securities law.


Skip Navigation Links.


JD, magna cum laude, Harvard Law School, 1993, President, Harvard Law Review

BA, Social Studies, magna cum laude, Harvard University, 1985

Bar Admissions


District of Columbia


The Hon. Abner J. Mikva, US Court of Appeals for the District of Columbia Circuit, 1993 - 1994